PCDH19 encodes protocadherin-19 (PCDH19), a non-clustered protocadherin of the cadherin superfamily. PCDH19 is expressed in excitatory neurons of the cerebral cortex, hippocampus, and cerebellum, where it functions as a homophilic cell adhesion molecule involved in neuronal wiring, dendritic arborization, and synaptic organization. Pathogenic variants in PCDH19 cause PCDH19 clustering epilepsy, a rare X-linked disorder that predominantly affects females, despite the gene being subject to X-linked inheritance with a unique female-biased phenotype.
The unusual inheritance pattern of PCDH19-related epilepsy — females affected, males unmasked or more mildly affected — is explained by cellular interference, where random X-inactivation creates a mosaic of wild-type and mutant cells that interferes with normal neural circuit formation.
| Property | Value |
|---|---|
| Gene Symbol | PCDH19 |
| Chromosomal Location | Xq13.3 |
| Genomic Coordinates | chrX:100,630,000-100,770,000 (GRCh38) |
| Gene Length | ~140 kb |
| Number of Exons | 6 coding exons |
| Protein Length | 1,118 amino acids |
| Protein Class | Protocadherin (non-clustered), cell adhesion molecule |
| Expression | Brain (cortex, hippocampus, cerebellum), neural tissue |
| Inheritance | X-linked; female-biased due to cellular interference |
| OMIM | 300460 |
| UniProt | Q9UN68 |
PCDH19 belongs to the protocadherin subfamily, which differs from classical cadherins:
PCDH19 functions as a homophilic cell adhesion molecule — it binds to itself on adjacent cells. This allows:
During neural development, PCDH19 expression helps:
The unique female-bias in PCDH19-related epilepsy is explained by the cellular interference mechanism:
Females (heterozygous): Random X-inactivation creates a mosaic of cells expressing either wild-type or mutant PCDH19. Heteromeric PCDH19 complexes (wild-type + mutant) are non-functional or unstable, while homomeric wild-type or homomeric mutant complexes are rare due to the mosaic. This widespread disruption of PCDH19 adhesive function in the female brain causes the full epilepsy phenotype.
Males (hemizygous): All cells express mutant PCDH19. No cellular mosaic — instead, all neurons have the same (mutant) PCDH19, and form homomeric mutant complexes that, while reduced in function, may still partially support normal circuit formation. Males are often clinically unaffected or more mildly affected.
Mosaic males: Rare cases of post-zygotic mosaicism in males can cause typical PCDH19 epilepsy.
Loss of functional PCDH19 leads to:
| Disorder | Mechanism | Key Features |
|---|---|---|
| PCDH19 clustering epilepsy | Heterozygous pathogenic variant (females) or hemizygous (males) | Focal seizures with clustering, intellectual disability, behavioral features |
| Early infantile epileptic encephalopathy-9 (EIEE9) | Severe PCDH19 variants | Refractory seizures, profound ID, onset <1 year |
| Isolated intellectual disability | Missense variants, males | Mild-moderate ID without epilepsy |
PCDH19 clustering epilepsy is typically refractory to standard anti-seizure medications. Limited data suggests:
PCDH19 is a strong candidate for gene therapy approaches:
Vigonvita Sciences has developed a PCDH19 gene therapy program targeting the wild-type PCDH19 coding sequence. Preclinical studies in Pcdh19 mouse models have demonstrated:
See Vigonvita PCDH19 preclinical page and therapeutics hub page.